TICKERNERD
Menu
CVKDCVKDHealthcare · Biotechnology

CVKD Stock Forecast: Cadrenal Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$1.96
−2.49% on the day

The 2 Wall Street analysts covering Cadrenal Therapeutics, Inc. hold a median 12-month price target of $13 — +563.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.2M
Ticker Nerd rank
36 / 100
Median analyst target
$13
Analysts covering
2
Total return, dividends reinvested
1W
−4.9%
1M
−45.6%
YTD
−71.1%
1Y
−81.0%
From 52W high
−86.2%
From 52W low
0.0%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVKD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cadrenal Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Growth
84
Revisions
67
Accruals
54
Issuance
32
Quality
31
Volatility
19
Value
13
Momentum
3

Size (94): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Cadrenal Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

CVKD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVKD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26CVKDHigh $25Median $13Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $12Median $13High $25

The green dot is the last close — the median target sits +563.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Apr 2026HC Wainwright & Co.MaintainsBuy$32 → $13
16 May 2025HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.MaintainsBuy—
6 June 2024HC Wainwright & Co.ReiteratesBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
14 Mar 2024HC Wainwright & Co.ReiteratesBuy—
18 Dec 2023Noble Capital MarketsInitiatesOutperform—
20 Nov 2023HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CVKD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Cadrenal Therapeutics, Inc. (CVKD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
2.8×

Cheaper than 35% of US stocks

EV / EBITDA
−0.3×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−300.6%

Higher than 4% of US stocks

Return on assets
−139.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CVKD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CVKDCadrenal Therapeutics, Inc.$6.2M
36
ACXPAcurx Pharmaceuticals, Inc.$6.2M
43
PMCBPharmaCyte Biotech, Inc.$6.2M
39
ALZNAlzamend Neuro, Inc.$6.3M
16
PULMPulmatrix, Inc.$6.4M
39
KAPAKairos Pharma Ltd.$6.6M
29
CURXCuranex Pharmaceuticals, Inc.$5.8M
4
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVKD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CVKD news & analysis

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation

GlobeNewsWire · 3 Aug 2026positive

Cadrenal Therapeutics announced a consolidation of its multi-indication strategy for its Cardiac Acute Critical Care franchise, focusing CAD-1005 on both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The update follows a competitor's discontinuation of a late-stage Phase 3 trial for lack of efficacy, which Cadrenal says highlights the need for novel upstream targets such as 12-LOX and supports CAD-1005's first-in-class positioning in the U.S. CSA-AKI market.

Why it matters — CAD-1005 is now positioned as a first-in-class candidate across two acute-care indications in a franchise central to CVKD's pipeline, with the rival program's failure leaving the high-value CSA-AKI market gap potentially open to it.

FAQ

Frequently asked questions about CVKD stock

What is the CVKD stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Cadrenal Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $12 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVKD stock a buy right now?

Of the 2 analysts covering Cadrenal Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cadrenal Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVKD?

As at 1 Aug 2026, Cadrenal Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will CVKD stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +563.3% from the last close, and Ticker Nerd's factor model ranks Cadrenal Therapeutics, Inc. 36 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVKD stock forecast for 2030?

No analyst covering Cadrenal Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVKD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $25 over the next 12 months.

How has CVKD stock performed over the past year?

Cadrenal Therapeutics, Inc. returned -81.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cadrenal Therapeutics, Inc. do?

Cadrenal Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions.

What is the latest news on CVKD?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation". Cadrenal Therapeutics announced a consolidation of its multi-indication strategy for its Cardiac Acute Critical Care franchise, focusing CAD-1005 on both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The update follows a competitor's discontinuation of a late-stage Phase 3 trial for lack of efficacy, which Cadrenal says highlights the need for novel upstream targets such as 12-LOX and supports CAD-1005's first-in-class positioning in the U.S. CSA-AKI market.

Company

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a phase 3-ready, first-in-class 12-LOX inhibitor designed to treat heparin-induced thrombocytopenia (HIT), a severe immune-mediated thrombotic disorder, by targeting the primary underlying immune mechanisms unlike existing treatments that only address complications. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, along with orphan drug status from the European Medicines Agency, and second-generation 12-LOX oral therapeutics are in development. The company's pipeline also features tecarfarin, a phase 3-ready oral vitamin K antagonist with a mechanism similar to warfarin but metabolized differently for potentially more reliable anticoagulation in patients with end-stage kidney disease and atrial fibrillation or those with left ventricular assist devices. Additionally, frunexian, a parenteral clinical-stage Factor XIa inhibitor, targets acute hospital settings, particularly complex cardiac surgeries involving medical devices. Cadrenal Therapeutics Inc. advances these investigational treatments to address unmet needs in critical care anticoagulation and immune disorders.

CEO Mr. Quang X. Pham · 5 employees · United States · https://www.cadrenal.com